# Chong Kun Dang Pharmaceutical Corp.

> Chong Kun Dang Pharmaceutical Corp. is a VC fund in Seoul backing Health Care and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Seoul, South Korea
- Total investments: 3
- Last investment: Feb 2022
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/chong-kun-dang-pharm./about/
- Website: http://www.ckdpharm.com/ckd/index.ckd

Chong Kun Dang Pharmaceutical Corp. is a Pharmaceutical company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| FinTech | 1 | 33% |
| Medical | 1 | 33% |
| Biopharma | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 67% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 2 | 67% |
| Israel | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BIORCHESTRA | BIORCHESTRA is a developer of RNA-based therapeutics. | $45.7M | Series C | Feb 22, 2022 |  |
| Nodit | Founded in 2012, Dunamu (CEO Lee Seok-woo) is currently providing services as the largest cryptocurrency exchange in Korea, 'Upbit'​ and stock trading platform based on social network, ‘Kakao Stock'​. Both services are leading in the industry and ecosystems. (Upbit launched in Oct. 2017, Kakao Stock launched in Feb. 2014) Dunamuprovides the best service in the fields of cryptocurrency, securities, and asset management. Dunamu is getting much attention in both domestic and global market with professional specialists, innovative services and excellent technology. Recently, it announced to make investment of 100 billion dollars in the blockchain industry, leading the way in creating blockchain ecosystem. | $60M | Series B | Dec 15, 2021 |  |
| BIOMx | BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $32M | Series B | Feb 20, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 2 deals together
- [SBI Investment Korea](https://shizune.co/investors/profile/sbi-investment-korea) — VC Fund, 2 deals together
- [Chong Kun Dang](https://shizune.co/investors/profile/chong-kun-dang) — VC Fund, 1 deal together
- [Consensus Business Group](https://shizune.co/investors/profile/consensus-business-group) — VC Fund, 1 deal together
- [Daelim Corporation](https://shizune.co/investors/profile/daelim-corporation) — VC Fund, 1 deal together
- [Dayli Partners](https://shizune.co/investors/profile/dayli-partners) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chong Kun Dang Pharmaceutical Corp. invest in?

Chong Kun Dang Pharmaceutical Corp. invests primarily in Health Care, Therapeutics and FinTech startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chong Kun Dang Pharmaceutical Corp. last invest?

The most recent investment recorded for Chong Kun Dang Pharmaceutical Corp. closed in Feb 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co